tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Fungemia D016469 2 associated lipids
Legionellosis D007876 3 associated lipids
Lung Abscess D008169 1 associated lipids
IgA Deficiency D017098 2 associated lipids
IgG Deficiency D017099 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Alopecia Areata D000506 6 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Polymyositis D017285 1 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Smooth Muscle Tumor D018235 1 associated lipids
Blepharitis D001762 4 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Trichomonas Vaginitis D014247 2 associated lipids
Hypopigmentation D017496 2 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Erythema Nodosum D004893 5 associated lipids
Sweet Syndrome D016463 1 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Deglutition Disorders D003680 2 associated lipids
Oral Ulcer D019226 1 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Leukemia, Myeloid, Chronic-Phase D015466 1 associated lipids
Lupus Erythematosus, Cutaneous D008178 2 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Epididymitis D004823 1 associated lipids
Orchitis D009920 1 associated lipids
Ichthyosiform Erythroderma, Congenital D016113 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Citrullinemia D020159 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Hand Injuries D006230 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Lichen Planus, Oral D017676 2 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Lichen Sclerosus et Atrophicus D018459 2 associated lipids
Leukemia, Biphenotypic, Acute D015456 2 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Pemphigus D010392 3 associated lipids
Mutism D009155 1 associated lipids
Neurodermatitis D009450 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Skin Diseases, Viral D017193 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Rectal Fistula D012003 2 associated lipids
Vestibular Diseases D015837 2 associated lipids
Intestinal Atresia D007409 3 associated lipids
Priapism D011317 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Trichomonas Infections D014245 3 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
West Nile Fever D014901 1 associated lipids
Foot Ulcer D016523 4 associated lipids
Fibroadenoma D018226 2 associated lipids
Tinea Capitis D014006 1 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Lymphocele D008210 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Angiofibroma D018322 2 associated lipids
Posterior Leukoencephalopathy Syndrome D054038 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Cheilitis D002613 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Hidradenitis Suppurativa D017497 2 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Optic Neuritis D009902 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Myelinolysis, Central Pontine D017590 1 associated lipids
Balanitis D001446 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
van den Berg JW et al. New immunosuppressive drugs and lung transplantation: last or least? 1999 Thorax pmid:10335012
Henley SA et al. Lipids increase after solitary pancreas transplantation. 1999 Diabetes Care pmid:10333952
Iwamoto H et al. Inhibitory effects of FK506 on the development of experimental allergic/immune-mediated blepharoconjunctivitis in Lewis rats by systemic but not by topical administration. 1999 Graefes Arch. Clin. Exp. Ophthalmol. pmid:10333108
Okamoto H The CD38-cyclic ADP-ribose signaling system in insulin secretion. 1999 Mol. Cell. Biochem. pmid:10331647
Dresske B et al. Synergistic impact of "WOFIE" on the immunosuppressive potency of FK 506 in a heterotopic heart transplantation model in the rat. 1999 Transplant. Proc. pmid:10331001
Nakamura H et al. Induction of autologous graft-versus-host disease after autologous peripheral blood stem cell transplantation. 1999 J. Allergy Clin. Immunol. pmid:10329849
Tian J and Karin M Stimulation of Elk1 transcriptional activity by mitogen-activated protein kinases is negatively regulated by protein phosphatase 2B (calcineurin). 1999 J. Biol. Chem. pmid:10329725
Kohyama T et al. A potent immunosuppressant FK506 inhibits IL-8 expression in human eosinophils. 1999 Mol. Cell Biol. Res. Commun. pmid:10329481
Schmidt RH et al. Haemolytic-uraemic syndrome after tacrolimus rescue therapy for cortisone-resistant rejection. 1999 Nephrol. Dial. Transplant. pmid:10328486
Ruzicka T et al. Tacrolimus: the drug for the turn of the millennium? 1999 Arch Dermatol pmid:10328199
Garrity ER et al. Suggested guidelines for the use of tacrolimus in lung-transplant recipients. 1999 J. Heart Lung Transplant. pmid:10328140
Raofi V et al. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. 1999 Am. J. Surg. pmid:10326847
Ferlicot S et al. [Smooth muscle mesentery associated with Epstein-Barr virus (EBV). Report of a case in a child with a liver transplant under FK506 regimen]. 1999 Ann Pathol pmid:10320913
Morioka M et al. Activities of calcineurin and phosphatase 2A in the hippocampus after transient forebrain ischemia. 1999 Brain Res. pmid:10320733
Genazzani AA et al. Calcineurin controls inositol 1,4,5-trisphosphate type 1 receptor expression in neurons. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10318964
Remy I and Michnick SW Clonal selection and in vivo quantitation of protein interactions with protein-fragment complementation assays. 1999 Proc. Natl. Acad. Sci. U.S.A. pmid:10318894
Stratta RJ et al. Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction. 1999 Ann. Surg. pmid:10235529
Akahane M et al. Osteogenic phenotype expression of allogeneic rat marrow cells in porous hydroxyapatite ceramics. 1999 J. Bone Miner. Res. pmid:10234577
Mollison KW et al. A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases. 1999 J. Invest. Dermatol. pmid:10233764
Jolles S et al. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. 1999 Br. J. Dermatol. pmid:10233301
Lyon CC et al. Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. 1999 Br. J. Dermatol. pmid:10233300
Vente C et al. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. 1999 Br. J. Dermatol. pmid:10233234
Johnston A and Holt DW Therapeutic drug monitoring of immunosuppressant drugs. 1999 Br J Clin Pharmacol pmid:10233195
Uno T et al. Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route. 1999 Lipids pmid:10230718
Göthel SF and Marahiel MA Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. 1999 Cell. Mol. Life Sci. pmid:10228556
Torocsik HV et al. FK506-induced leukoencephalopathy in children with organ transplants. 1999 Neurology pmid:10227644
Taylor DO et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. 1999 J. Heart Lung Transplant. pmid:10226898
Charco R et al. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy. 1999 Liver Transpl Surg pmid:10226111
Herr I et al. FK506 prevents stroke-induced generation of ceramide and apoptosis signaling. 1999 Brain Res. pmid:10224298
Ferrari D et al. P2X7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. 1999 J. Biol. Chem. pmid:10224077
Green MD and Michaels MG Tacrolimus: effects and side effects. 1999 Pediatr. Infect. Dis. J. pmid:10223694
Knoll GA and Bell RC Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. 1999 BMJ pmid:10213717
Jani A et al. Modulation of cell-mediated immunity prolongs adenovirus-mediated transgene expression in sciatic nerve. 1999 Hum. Gene Ther. pmid:10210146
Lütkes P et al. [Quality of life following transplantation. The impact ofa new immunosuppressive substance]. 1999 Zentralbl Chir pmid:10209841
Cetinkale O et al. Modulating the functions of neutrophils and lipid peroxidation by FK506 in a rat model of thermal injury. 1999 Burns pmid:10208383
Hortelano S et al. Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. 1999 Br. J. Pharmacol. pmid:10205001
Nagasaki Y et al. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. 1999 Pediatr. Res. pmid:10203136
Sloper CM et al. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. 1999 Ophthalmology pmid:10201592
De Lima JJ et al. Effects of FK506 in rat and human resistance arteries. 1999 Kidney Int. pmid:10201018
Mollison KW et al. Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases. 1998 Curr. Pharm. Des. pmid:10197049
Azuma N et al. Immunosuppression with FK506 in rat arterial allografts: fate of allogeneic endothelial cells. 1999 J. Vasc. Surg. pmid:10194498
Meiser BM et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. 1999 J. Heart Lung Transplant. pmid:10194038
Fansa H et al. The effect of the immunosuppressant FK 506 on peripheral nerve regeneration following nerve grafting. 1999 J Hand Surg Br pmid:10190602
Zhang W et al. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. 1999 Circ. Res. pmid:10189360
Yasutsune T et al. Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery. 1999 Br. J. Pharmacol. pmid:10188984
Antoniou EA et al. Immunosuppressive effect of combination schedules of brequinar with leflunomide or tacrolimus on rat cardiac allotransplantation. 1999 Microsurgery pmid:10188834
Holländer GA et al. Molecular and biological actions of cyclosporin A and FK506 on T cell development and function. 1994 Transfus Sci pmid:10155542
Hemenway CS and Heitman J Calcineurin. Structure, function, and inhibition. 1999 Cell Biochem. Biophys. pmid:10099825
Shapiro R et al. Posttransplant diabetes in pediatric recipients on tacrolimus. 1999 Transplantation pmid:10096540
Nogueira JM et al. A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. 1999 Transplantation pmid:10096529
Pompeo A et al. Cyclosporin A, but not FK506, increases arachidonic acid release and inhibits proliferation of pituitary corticotrope tumor cells. 1999 Life Sci. pmid:10096434
Kenyon NS et al. Islet transplantation: present and future perspectives. 1998 Diabetes Metab Rev pmid:10095999
Nakahama H et al. Effect of FK 506 in the treatment of autoimmune glomerulonephritis in Brown Norway rats. 1999 Nephron pmid:10095178
Kimura T et al. N-glycosylation is involved in the sensitivity of Saccharomyces cerevisiae to HM-1 killer toxin secreted from Hansenula mrakii IFO 0895. 1999 Appl. Microbiol. Biotechnol. pmid:10091323
Crabtree GR Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. 1999 Cell pmid:10089876
Liang J et al. Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. 1999 Acta Crystallogr. D Biol. Crystallogr. pmid:10089303
Trimbur GM et al. Cloning, sequencing, and nucleolar targeting of the basal-body-binding nucleolar protein BN46/51. 1999 J. Cell. Sci. pmid:10085251
Yura H et al. Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. 1999 J Control Release pmid:10084872
Webber SA 15 years of pediatric heart transplantation at the University of Pittsburgh: lessons learned and future prospects. 1997 Pediatr Transplant pmid:10084782
Atkison P et al. Small bowel transplantation in children. 1997 Pediatr Transplant pmid:10084770
Shapiro R Tacrolimus in pediatric renal transplantation: a review. 1998 Pediatr Transplant pmid:10084728
Vieregge B et al. Synergistic effects of the alkaloid sinomenine in combination with the immunosuppressive drugs tacrolimus and mycophenolic acid. 1999 Planta Med. pmid:10083851
Cirocco RE et al. Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay. 1999 Feb-Mar Transplant. Proc. pmid:10083604
Fu F et al. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. 1999 Feb-Mar Transplant. Proc. pmid:10083555
Chiba K et al. FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. 1999 Feb-Mar Transplant. Proc. pmid:10083549
Hoshino Y et al. FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. 1999 Feb-Mar Transplant. Proc. pmid:10083547
Jiang H et al. Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. 1999 Feb-Mar Transplant. Proc. pmid:10083538
Schorlemmer HU et al. Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. 1999 Feb-Mar Transplant. Proc. pmid:10083529
Wu MS et al. Cyclosporine, but not FK506 and rapamycin, enhances Na(+)-K(+)-CL- cotransport activity in cultured medullary thick ascending limb cells. 1999 Feb-Mar Transplant. Proc. pmid:10083527
Yamashita K et al. Effect of a novel immunosuppressant, FTY720, on heart and liver transplantations in rats. 1999 Feb-Mar Transplant. Proc. pmid:10083526
Mohamed MA et al. The effect of cyclosporin A and tacrolimus on cultured human epithelial cells: the role of TGF-beta. 1999 Feb-Mar Transplant. Proc. pmid:10083523
Zanker B et al. Comparison of MPA trough levels in patients with severe diabetes mellitus and from non-diabetics after transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083521
Zuckermann A et al. Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083518
Kokado Y et al. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083515
Opelz G Immunosuppression with FK 506 does not improve kidney graft survival. Collaborative Transplant Study. 1999 Feb-Mar Transplant. Proc. pmid:10083513
Shapiro R et al. A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. 1999 Feb-Mar Transplant. Proc. pmid:10083507
Steinmueller T et al. The effect of cyclosporine vs FK 506 on glucose metabolism. 1999 Feb-Mar Transplant. Proc. pmid:10083504
Yang HC et al. Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial. 1999 Feb-Mar Transplant. Proc. pmid:10083501
Klupp J et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083497
McAlister VC et al. Oral delivery of liposomal tacrolimus: increased efficacy and reduced toxicity. 1999 Feb-Mar Transplant. Proc. pmid:10083495
Navia MA Rational design of new immunosuppressive drugs. 1999 Feb-Mar Transplant. Proc. pmid:10083489
Song Z et al. FK 506 prevents islet xenograft rejection: a study in the pig-to-rat model. 1999 Feb-Mar Transplant. Proc. pmid:10083437
Terakura M et al. Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083380
Kaibori M et al. Inhibition of iNOS induction by FK506, but not by cyclosporine, in rat hepatocytes. 1999 Feb-Mar Transplant. Proc. pmid:10083347
Rao AS et al. Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions. 1999 Feb-Mar Transplant. Proc. pmid:10083302
Rastellini C et al. Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. 1999 Feb-Mar Transplant. Proc. pmid:10083278
Stratta RJ Optimal immunosuppression in pancreas transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083263
Kaufman DB et al. Single-center experience of 60 consecutive simultaneous pancreas-kidney transplants using mycophenolate mofetil and tacrolimus as primary maintenance immunotherapy. 1999 Feb-Mar Transplant. Proc. pmid:10083261
Humar A et al. Surgical complications requiring early relaparotomy after pancreas transplantation: comparison of the cyclosporine and FK 506 eras. 1999 Feb-Mar Transplant. Proc. pmid:10083256
Kandaswamy R et al. Vascular graft thrombosis after pancreas transplantation: comparison of the FK 506 and cyclosporine eras. 1999 Feb-Mar Transplant. Proc. pmid:10083254
Damotte D et al. Morphologic features of large bowel biopsies in combined small and large bowel transplantations could predict clinical rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083252
Schulz T et al. Mycophenolate mofetil/prednisolone/single-shot ATG with tacrolimus or cyclosporine in pancreas/kidney transplantation: first results of an ongoing prospective randomized trial. 1999 Feb-Mar Transplant. Proc. pmid:10083251
Murase N et al. Immunomodulation of intestinal transplant with allograft irradiation and simultaneous donor bone marrow infusion. 1999 Feb-Mar Transplant. Proc. pmid:10083238
Fischer L et al. Hepatitis G virus infection in liver transplant recipients. 1999 Feb-Mar Transplant. Proc. pmid:10083208
Rayes N et al. Treatment of hepatitis B-reinfection or de novo-infection after liver transplantation with famciclovir--how effective is it? 1999 Feb-Mar Transplant. Proc. pmid:10083200
Molmenti E et al. Noncompliance after pediatric liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083164
Mueller AR et al. Is the use of marginal liver grafts justified? 1999 Feb-Mar Transplant. Proc. pmid:10083160
Kato T et al. Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083158
Lohmann R et al. Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083151
Tacrolimus in renal transplantation: a comparison of induction vs noninduction therapy (triple therapy): three-month results. 1999 Feb-Mar Transplant. Proc. pmid:10083131